Head-to-head · WeighScore
Luma Health Co vs Revel RX
The verdict
Revel RX takes it — 77.3/100 to 74.8/100.
Revel RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Revel RX is a Michigan-based telehealth weight-loss platform offering compounded semaglutide at $89/month and compounded tirzepatide at $155/month — flat-rate at every dose tier.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Luma Health Co | Revel RX |
|---|---|---|
| WeighScore | 74.8/100 | 77.3/100 |
| Grade | C | C+ |
| Scorecard rank | #62 | #47 |
| Semaglutide | $120/mo (plus a separate fee, compounded) | $89/mo (all doses, compounded) |
| Tirzepatide | $180/mo (compounded) | $155/mo (all doses, compounded) |
| Coverage | 30 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #62 · C
Strengths
- Transparent, competitive pricing published up front — compounded semaglutide from $120/mo, tirzepatide from $180/mo, retatrutide from $170/mo
- No subscription, monthly fee or membership — a direct-to-patient model where you pay per medication, and follow-up visits are free
- Free initial consults for first responders, law enforcement, military, nurses and teachers ($0), and $25 for other healthcare workers
- Founded and led by a named family nurse practitioner (Tiffani McKnight, FNP-C) licensed across 30 states/DC, with HIPAA-compliant virtual visits
- HSA/FSA funds and financing accepted, with itemized invoices for HSA/FSA submission
Where it loses points
- Offers compounded retatrutide (labeled "RTT/GLP-3"), an investigational triple agonist not FDA-approved — a higher-risk, less-studied option
- Compounded medications only — no brand-name Wegovy, Zepbound or Ozempic — and compounded GLP-1s aren't FDA-reviewed or approved
- No LegitScript certification shown and no compounding-pharmacy partner named, so the dispensing pharmacy can't be independently verified
- Small, newly established founder-led practice with a thin website and limited public track record or third-party reviews
- Medication prices are "starting at" and billed on top of a one-time consult fee, so the true first-month cost runs higher than the headline
Graded #47 · C+
Strengths
- Industry-low flat pricing: $89/mo for compounded semaglutide and $155/mo for tirzepatide at every dose
- LegitScript verified and BBB accredited with an A+ rating — above-average trust signals for a compounded platform
- Named pharmacy partners: Manifest Pharmacy and Red Rock Home Pharmacy (503A + 503B facilities)
- Free overnight cold shipping included; no hidden fees or dose-based price increases
- Clinical review by MD Integrations, an independent medical group, before any prescription is issued
Where it loses points
- States served are not publicly listed; eligible states requires completing intake to confirm coverage
- No labs, coaching, or ongoing health support disclosed in any public materials
- Compounded medications are not FDA-approved (site discloses this)
- Newer brand with limited public patient reviews or Trustpilot rating
- Pharmacy partners named but no accreditation details (PCAB, 503B cGMP) published on the site
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.